Annual Accounts Receivable
$8.88 B
+$731.00 M+8.97%
31 December 2023
Summary:
Bristol-Myers Squibb annual accounts receivable is currently $8.88 billion, with the most recent change of +$731.00 million (+8.97%) on 31 December 2023. During the last 3 years, it has risen by +$903.00 million (+11.32%). BMY annual accounts receivable is now at all-time high.BMY Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$9.32 B
-$429.00 M-4.40%
30 September 2024
Summary:
Bristol-Myers Squibb quarterly accounts receivable is currently $9.32 billion, with the most recent change of -$429.00 million (-4.40%) on 30 September 2024. Over the past year, it has increased by +$435.00 million (+4.90%). BMY quarterly accounts receivable is now -4.40% below its all-time high of $9.75 billion, reached on 30 June 2024.BMY Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMY Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +4.9% |
| 3 y3 years | +11.3% | +16.8% |
| 5 y5 years | +37.1% | +43.9% |
BMY Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +11.3% | -4.4% | +30.2% |
| 5 y | 5 years | at high | +37.1% | -4.4% | +43.9% |
| alltime | all time | at high | +425.6% | -4.4% | +474.1% |
Bristol-Myers Squibb Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $9.32 B(-4.4%) |
| June 2024 | - | $9.75 B(+10.4%) |
| Mar 2024 | - | $8.83 B(-0.6%) |
| Dec 2023 | $8.88 B(+9.0%) | $8.88 B(+5.7%) |
| Sept 2023 | - | $8.41 B(+3.5%) |
| June 2023 | - | $8.13 B(+3.5%) |
| Mar 2023 | - | $7.85 B(-3.6%) |
| Dec 2022 | $8.15 B(+2.2%) | $8.15 B(+1.6%) |
| Sept 2022 | - | $8.02 B(+5.7%) |
| June 2022 | - | $7.59 B(+6.0%) |
| Mar 2022 | - | $7.16 B(-10.3%) |
| Dec 2021 | $7.98 B(+10.5%) | $7.98 B(+1.3%) |
| Sept 2021 | - | $7.88 B(+2.1%) |
| June 2021 | - | $7.71 B(+7.3%) |
| Mar 2021 | - | $7.19 B(-0.4%) |
| Dec 2020 | $7.22 B(+11.5%) | $7.22 B(+6.5%) |
| Sept 2020 | - | $6.78 B(+1.2%) |
| June 2020 | - | $6.70 B(-7.0%) |
| Mar 2020 | - | $7.20 B(+11.2%) |
| Dec 2019 | $6.48 B(+39.7%) | $6.48 B(+51.0%) |
| Sept 2019 | - | $4.29 B(-4.8%) |
| June 2019 | - | $4.50 B(-2.0%) |
| Mar 2019 | - | $4.59 B(-0.9%) |
| Dec 2018 | $4.64 B(+6.6%) | $4.64 B(+0.3%) |
| Sept 2018 | - | $4.62 B(+6.9%) |
| June 2018 | - | $4.32 B(-1.2%) |
| Mar 2018 | - | $4.37 B(+0.6%) |
| Dec 2017 | $4.35 B(+15.2%) | $4.35 B(+0.3%) |
| Sept 2017 | - | $4.33 B(+2.7%) |
| June 2017 | - | $4.22 B(+3.3%) |
| Mar 2017 | - | $4.08 B(+8.2%) |
| Dec 2016 | $3.77 B(+28.0%) | $3.77 B(-1.0%) |
| Sept 2016 | - | $3.81 B(+3.5%) |
| June 2016 | - | $3.69 B(+9.6%) |
| Mar 2016 | - | $3.36 B(+14.1%) |
| Dec 2015 | $2.95 B(+40.4%) | $2.95 B(+8.6%) |
| Sept 2015 | - | $2.71 B(+6.7%) |
| June 2015 | - | $2.54 B(+13.0%) |
| Mar 2015 | - | $2.25 B(+7.1%) |
| Dec 2014 | $2.10 B(+24.3%) | $2.10 B(+15.2%) |
| Sept 2014 | - | $1.82 B(+1.3%) |
| June 2014 | - | $1.80 B(+3.3%) |
| Mar 2014 | - | $1.74 B(+3.1%) |
| Dec 2013 | $1.69 B | $1.69 B(-8.1%) |
| Sept 2013 | - | $1.84 B(-0.6%) |
| June 2013 | - | $1.85 B(+2.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $1.80 B(+5.3%) |
| Dec 2012 | $1.71 B(-24.1%) | $1.71 B(-1.5%) |
| Sept 2012 | - | $1.73 B(+6.8%) |
| June 2012 | - | $1.62 B(-55.1%) |
| Mar 2012 | - | $3.61 B(+60.6%) |
| Dec 2011 | $2.25 B(-46.9%) | $2.25 B(+3.2%) |
| Sept 2011 | - | $2.18 B(+3.1%) |
| June 2011 | - | $2.12 B(+3.4%) |
| Mar 2011 | - | $2.05 B(+13.4%) |
| June 2010 | - | $1.80 B(-57.3%) |
| Sept 2008 | - | $4.22 B(-5.5%) |
| June 2008 | - | $4.47 B(-1.6%) |
| Mar 2008 | - | $4.54 B(+7.1%) |
| Dec 2007 | $4.24 B(+30.6%) | $4.24 B(+14.5%) |
| Sept 2007 | - | $3.70 B(+2.0%) |
| June 2007 | - | $3.63 B(+7.4%) |
| Mar 2007 | - | $3.38 B(+4.1%) |
| Dec 2006 | $3.25 B(-3.9%) | $3.25 B(+10.3%) |
| Sept 2006 | - | $2.94 B(-11.5%) |
| June 2006 | - | $3.33 B(+2.8%) |
| Mar 2006 | - | $3.24 B(-4.2%) |
| Dec 2005 | $3.38 B(-22.8%) | $3.38 B(+2.2%) |
| Sept 2005 | - | $3.31 B(-0.3%) |
| June 2005 | - | $3.31 B(-9.1%) |
| Mar 2005 | - | $3.65 B(-16.6%) |
| Dec 2004 | $4.37 B(+19.5%) | $4.37 B(+14.8%) |
| Sept 2004 | - | $3.81 B(+8.6%) |
| June 2004 | - | $3.51 B(+12.9%) |
| Mar 2004 | - | $3.11 B(-15.1%) |
| Dec 2003 | $3.66 B(+23.3%) | $3.66 B(+2.0%) |
| Sept 2003 | - | $3.59 B(+11.7%) |
| June 2003 | - | $3.21 B(+0.8%) |
| Mar 2003 | - | $3.19 B(+7.4%) |
| Dec 2002 | $2.97 B(-25.7%) | $2.97 B(-17.9%) |
| Sept 2002 | - | $3.62 B(+4.2%) |
| June 2002 | - | $3.47 B(-3.6%) |
| Mar 2002 | - | $3.60 B(-9.8%) |
| Dec 2001 | $3.99 B(+9.0%) | $3.99 B(+6.8%) |
| Sept 2001 | - | $3.74 B(+5.3%) |
| June 2001 | - | $3.55 B(-10.0%) |
| Mar 2001 | - | $3.95 B(+7.8%) |
| Dec 2000 | $3.66 B(+11.9%) | $3.66 B(-3.2%) |
| Sept 2000 | - | $3.78 B(+15.6%) |
| Dec 1999 | $3.27 B(+2.6%) | $3.27 B(+2.6%) |
| Dec 1998 | $3.19 B(+7.3%) | $3.19 B(+1.9%) |
| Sept 1998 | - | $3.13 B(+5.2%) |
| Dec 1997 | $2.97 B | $2.97 B |
FAQ
- What is Bristol-Myers Squibb annual accounts receivable?
- What is the all time high annual accounts receivable for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Bristol-Myers Squibb?
- What is Bristol-Myers Squibb quarterly accounts receivable year-on-year change?
What is Bristol-Myers Squibb annual accounts receivable?
The current annual accounts receivable of BMY is $8.88 B
What is the all time high annual accounts receivable for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high annual accounts receivable is $8.88 B
What is Bristol-Myers Squibb quarterly accounts receivable?
The current quarterly accounts receivable of BMY is $9.32 B
What is the all time high quarterly accounts receivable for Bristol-Myers Squibb?
Bristol-Myers Squibb all-time high quarterly accounts receivable is $9.75 B
What is Bristol-Myers Squibb quarterly accounts receivable year-on-year change?
Over the past year, BMY quarterly accounts receivable has changed by +$435.00 M (+4.90%)